Portland, OR -- (SBWIRE) -- 07/18/2017 -- Parkinson's disease is a progressive, degenerative neurological motor disorder, primarily affecting the dopaminergic cells of the brain. The symptoms of this disease include rigidity, tremor, bradykinesia and postural instability. The global Parkinson's disease drug market has witnessed remarkable growth in recent years owing to a large patient pool and increased diagnosis rates. According to the Parkinson's Disease Foundation, there are about 10 million people suffering from Parkinson's disease globally. Parkinson's disease is an idiopathic disease occurring due to unknown causes.
Get full summary of the Report: https://www.alliedmarketresearch.com/parkinsons-disease-drug-market
Rising old age population and higher incidences of neurodegenerative diseases are two significant factors that drive the growth of this market. Moreover, increasing R&D investment and number of drugs in the pipeline are further expected to fuel the market growth. However, high cost of treatment and lack of expertise for early diagnosis is likely to curtail the market growth.The global Parkinson's disease market is segmented on the basis of drug type and geography. According to drug type, the market is segmented into, marketed and pipeline drugs.
Get sample of the Report: https://www.alliedmarketresearch.com/request-toc-and-sample/683
Recently, Impax Pharmaceuticals has announced the FDA approval for RYTARY, an extended release oral capsule for the treatment of Parkinson's disease. Similarly AbbVie received a US FDA approval for DUOPA, used in the the treatment of motor symptoms associated with Parkinson's disease.The companies profiled in this report include, Pfizer, Inc., Medtronic plc, Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, C.H. Boehringer Sohn AG & Ko. KG, Impax Laboratories, Inc., Abbvie Inc., and F. Hoffmann-La Roche AG.
Early buyers will receive 20% customization on this report
KEY MARKET SEGMENTS:
The global Parkinson's disease market is segmented below:
Parkinson's Disease Market - By Drug Type
- Marketed Drugs
- Dopamine agonists
- Glutamate antagonist
- COMT inhibitors
- MAO-B inhibitors
- Pipeline Drugs
Parkinson's Disease Market - By Geography
- North America